Pfizer Inc (PFE) 34.64 $PFE Merck KGaA's Q4 Net
Post# of 64074
Posted On: 03/04/2015 6:39:18 PM
Pfizer Inc (PFE) 34.64 $PFE
Merck KGaA's Q4 Net Income Flat Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:40AM CST
Merck KGaA's (MKGAF) net income during the fourth quarter of 2014 came in at 280 million euros compared with 280.6 million euros in the year-ago period.
PFE: 34.64 (+0.08), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
3 Companies That Could Unlock Shareholder Value Through a Split or Spinoff
Motley Fool Staff - Motley Fool - Wed Mar 04, 8:08AM CST
There are a number of reasons companies might consider spinning off parts of their operations. A spinoff may happen if a company's sales are sliding and it needs to raise cash. In other cases, activist investors lobby aggressively for a spinoff after...
GE: 25.66 (-0.20), PFE: 34.64 (+0.08), CMG: 664.16 (-4.27), C: 53.67 (-0.06), SYF: 31.89 (-0.25), HSP: 87.95 (+0.24), YUM: 80.08 (-1.43)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 70.16 (+1.50), JAZZ: 172.74 (-3.56), AZN: 67.79 (-0.49), PFE: 34.64 (+0.08)
Pfizer's
at Investor's Business Daily - Tue Mar 03, 5:33PM CST
Pfizer's (PFE) blockbuster vaccine Prevnar 13, which shields against 13 strains of pneumococcal disease, has been approved for use in EU residents 18 and up. Shares fell 0.6% to 34.56.
PFE: 34.64 (+0.08)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Pfizer's (PFE) CEO Ian Read Presents at Cowen and Company 35th Annual Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:18PM CST
PFE: 34.64 (+0.08)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Expanded label for Pfizer's Prevenar 13 pneumonia vaccine cleared in Europe
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
PFE: 34.64 (+0.08)
5 Common Errors Of A Dividend Growth Forecast
Kurtis Hemmerling - at Seeking Alpha - Tue Mar 03, 7:52AM CST
HI: 31.17 (-0.71), RF: 9.55 (-0.07), HSY: 101.53 (-1.02), GPC: 94.04 (-1.47), CAG: 34.52 (-0.44), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), RRD: 19.54 (+0.23), GWW: 236.00 (-5.29), TGT: 77.72 (-0.28), LOW: 74.02 (-0.99), BCR: 167.66 (+0.48), PFE: 34.64 (+0.08), VFC: 76.49 (-0.20), FDO: 78.59 (-0.07), MHFI: 102.55 (-1.07), MO: 55.79 (-0.67), WBA: 83.02 (-0.19), ADP: 86.57 (-2.13), ADM: 47.08 (-0.44), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), CTL: 36.25 (-1.43), MMM: 167.16 (-1.11), TE: 19.23 (-0.05), GE: 25.66 (-0.20), BDX: 148.36 (+2.10), HBAN: 10.82 (-0.10), KMB: 108.37 (-1.89), AON: 99.63 (-0.29), CB: 100.11 (-0.91), KEY: 13.90 (-0.10), K: 64.72 (-0.04), PEP: 97.36 (-1.04), SWK: 97.32 (-1.06), JNJ: 101.65 (-0.69), AVY: 53.23 (-0.03), CMA: 45.68 (-0.02), PPG: 235.34 (+0.80), KO: 42.50 (-0.45), XEL: 34.58 (-0.11), ABT: 47.01 (-0.08), NUE: 47.41 (+0.26), SVU: 10.18 (+0.28), EMR: 57.78 (-0.60), LEG: 45.37 (-0.38), LLY: 70.65 (+0.28), ITW: 98.20 (-1.47), PLL: 101.79 (-0.70), USB: 44.41 (-0.34), GCI: 34.77 (-0.76), PG: 84.35 (-0.81), JCI: 50.70 (-0.75)
Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults
Business Wire - Tue Mar 03, 7:35AM CST
Pfizer Inc. (NYSE
FE) announced today that the European Commission approved an expanded indication for the use of Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer's landmark Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease (IPD) in adults aged 65 and older.
PFE: 34.64 (+0.08)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 58.07 (+2.09), PFE: 34.64 (+0.08), ACOR: 35.74 (+0.54)
Boehringer Ingelheim submits regulatory apps for anticoagulant reversal agent
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:25AM CST
JNJ: 101.65 (-0.69), PFE: 34.64 (+0.08), BMY: 65.67 (+3.75)
Atara Biotherapeutics Names David A. Carmel as Head of Immunotherapy
GlobeNewswire - Tue Mar 03, 5:30AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced today that it has hired David A. Carmel as Head of Immunotherapy. Mr. Carmel will lead Atara's efforts in its collaboration with Memorial Sloan-Kettering Cancer Center (MSK) to develop and commercialize allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. The collaboration will initially focus on development and regulatory activities for the three clinical stage targeted T-cell programs that Atara believes offer the most rapid path to marketing approvals. Atara and MSK also intend to expand research and development through sponsored research funded by Atara. Atara recently announced that MSK received breakthrough therapy designation from the U.S. Food and Drug Administration for its cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV - CTL) in the treatment of patients with rituxamab-refractory, EBV-associated lymphoproliferative disease.
PFE: 34.64 (+0.08), ATRA: 26.55 (+4.53)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.08 (-0.01), VIVO: 20.06 (+0.06), PETS: 15.08 (-0.05), PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), MSA: 48.84 (-0.87), PDLI: 6.96 (-0.06), BAX: 69.25 (-0.17), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), STJ: 67.14 (-0.46), TRIB: 18.60 (+0.17), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65), THRX: 19.64 (+0.08), SNY: 48.34 (+0.26)
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 22 Companies & 81 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dj7p3w/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Bioblast Pharma Ltd. - Cellular Biomedicine Group, Inc. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - OrphageniX, Inc. - Paratek Pharmaceuticals, Inc. - Pfizer Inc. - PTC Therapeutics, Inc. - Retrophin Inc. - Sarepta Therapeutics, Inc. - Trophos SA - Vybion, Inc. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/dj...l_muscular
CYTK: 7.95 (-0.02), ISIS: 70.16 (+1.50), SRPT: 14.06 (+0.70), PFE: 34.64 (+0.08), RTRX: 14.04 (+0.17), PTCT: 70.45 (+1.37), PRTK: 29.54 (-0.03), CBMG: 29.50 (-0.34), NVS: 99.04 (-0.02)
Myasthenia Gravis Therapeutics Pipeline Review H1 2015
M2 - Tue Mar 03, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/9vr3t8/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2015" report to their offering. Myasthenia Gravis - Pipeline Review, H1 2015', provides an overview of the Myasthenia Gravis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Astellas Pharma Inc. - Biokine Therapeutics Ltd. - CuraVac, Inc. - Cytokinetics, Inc. - GlaxoSmithKline plc - Grifols, S.A. - HanAll Biopharma Co., Ltd. - Neurotune AG - Pfizer Inc. - Regenesance BV - Toleranzia AB Drug Profiles - ALN-CC5 - belimumab - BKT-130 - CK-2066260 - eculizumab - GL-2045 - HL-161 - immune globulin (human) - NT-1654 - Recombinant Protein for Myasthenia Gravis - Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Regenemab - tacrolimus - tirasemtiv - Vaccine for Myasthenia Gravis For more information visit http://www.researchandmarkets.com/research/9v...nia_gravis
CYTK: 7.95 (-0.02), PFE: 34.64 (+0.08), ALXN: 182.53 (+0.02), GSK: 47.82 (+0.11)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 34.64 (+0.08), OPHT: 53.91 (+0.04), GSK: 47.82 (+0.11), PFNX: 13.60 (-0.67), LPTN: 2.93 (-0.02), AGN: 235.68 (+0.82), AAVL: 36.61 (+1.92), OHRP: 10.72 (+0.37), NVS: 99.04 (-0.02)
The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly
Dividend House - at Seeking Alpha - Mon Mar 02, 11:51PM CST
KMI: 41.04 (-0.05), ABT: 47.01 (-0.08), HAS: 62.43 (-0.29), GE: 25.66 (-0.20), MAIN: 31.12 (-0.11), HTGC: 14.46 (-0.02), TCAP: 24.60 (+0.07), DLR: 65.60 (-1.12), PFE: 34.64 (+0.08), WMT: 82.58 (-0.79), WFC: 54.82 (-0.63), UL: 43.72 (-0.33), O: 50.34 (-0.21), BMY: 65.67 (+3.75), VOD: 34.60 (-0.02), DEO: 117.00 (-0.22), TUP: 70.93 (-0.18), WTR: 26.29 (-0.16), WBA: 83.02 (-0.19), CBRL: 149.57 (-2.19), MAT: 26.38 (-0.52), OHI: 40.11 (-0.15), ABBV: 60.27 (+0.65), AFL: 62.35 (+0.07), BBL: 48.50 (-0.80), CMCSA: 60.43 (+0.47), OMI: 34.97 (-0.36)
Merck KGaA's Q4 Net Income Flat Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:40AM CST
Merck KGaA's (MKGAF) net income during the fourth quarter of 2014 came in at 280 million euros compared with 280.6 million euros in the year-ago period.
PFE: 34.64 (+0.08), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
3 Companies That Could Unlock Shareholder Value Through a Split or Spinoff
Motley Fool Staff - Motley Fool - Wed Mar 04, 8:08AM CST
There are a number of reasons companies might consider spinning off parts of their operations. A spinoff may happen if a company's sales are sliding and it needs to raise cash. In other cases, activist investors lobby aggressively for a spinoff after...
GE: 25.66 (-0.20), PFE: 34.64 (+0.08), CMG: 664.16 (-4.27), C: 53.67 (-0.06), SYF: 31.89 (-0.25), HSP: 87.95 (+0.24), YUM: 80.08 (-1.43)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 70.16 (+1.50), JAZZ: 172.74 (-3.56), AZN: 67.79 (-0.49), PFE: 34.64 (+0.08)
Pfizer's
at Investor's Business Daily - Tue Mar 03, 5:33PM CST
Pfizer's (PFE) blockbuster vaccine Prevnar 13, which shields against 13 strains of pneumococcal disease, has been approved for use in EU residents 18 and up. Shares fell 0.6% to 34.56.
PFE: 34.64 (+0.08)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Pfizer's (PFE) CEO Ian Read Presents at Cowen and Company 35th Annual Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:18PM CST
PFE: 34.64 (+0.08)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Expanded label for Pfizer's Prevenar 13 pneumonia vaccine cleared in Europe
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
PFE: 34.64 (+0.08)
5 Common Errors Of A Dividend Growth Forecast
Kurtis Hemmerling - at Seeking Alpha - Tue Mar 03, 7:52AM CST
HI: 31.17 (-0.71), RF: 9.55 (-0.07), HSY: 101.53 (-1.02), GPC: 94.04 (-1.47), CAG: 34.52 (-0.44), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), RRD: 19.54 (+0.23), GWW: 236.00 (-5.29), TGT: 77.72 (-0.28), LOW: 74.02 (-0.99), BCR: 167.66 (+0.48), PFE: 34.64 (+0.08), VFC: 76.49 (-0.20), FDO: 78.59 (-0.07), MHFI: 102.55 (-1.07), MO: 55.79 (-0.67), WBA: 83.02 (-0.19), ADP: 86.57 (-2.13), ADM: 47.08 (-0.44), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), CTL: 36.25 (-1.43), MMM: 167.16 (-1.11), TE: 19.23 (-0.05), GE: 25.66 (-0.20), BDX: 148.36 (+2.10), HBAN: 10.82 (-0.10), KMB: 108.37 (-1.89), AON: 99.63 (-0.29), CB: 100.11 (-0.91), KEY: 13.90 (-0.10), K: 64.72 (-0.04), PEP: 97.36 (-1.04), SWK: 97.32 (-1.06), JNJ: 101.65 (-0.69), AVY: 53.23 (-0.03), CMA: 45.68 (-0.02), PPG: 235.34 (+0.80), KO: 42.50 (-0.45), XEL: 34.58 (-0.11), ABT: 47.01 (-0.08), NUE: 47.41 (+0.26), SVU: 10.18 (+0.28), EMR: 57.78 (-0.60), LEG: 45.37 (-0.38), LLY: 70.65 (+0.28), ITW: 98.20 (-1.47), PLL: 101.79 (-0.70), USB: 44.41 (-0.34), GCI: 34.77 (-0.76), PG: 84.35 (-0.81), JCI: 50.70 (-0.75)
Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults
Business Wire - Tue Mar 03, 7:35AM CST
Pfizer Inc. (NYSE
FE) announced today that the European Commission approved an expanded indication for the use of Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer's landmark Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease (IPD) in adults aged 65 and older. PFE: 34.64 (+0.08)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 58.07 (+2.09), PFE: 34.64 (+0.08), ACOR: 35.74 (+0.54)
Boehringer Ingelheim submits regulatory apps for anticoagulant reversal agent
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:25AM CST
JNJ: 101.65 (-0.69), PFE: 34.64 (+0.08), BMY: 65.67 (+3.75)
Atara Biotherapeutics Names David A. Carmel as Head of Immunotherapy
GlobeNewswire - Tue Mar 03, 5:30AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced today that it has hired David A. Carmel as Head of Immunotherapy. Mr. Carmel will lead Atara's efforts in its collaboration with Memorial Sloan-Kettering Cancer Center (MSK) to develop and commercialize allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. The collaboration will initially focus on development and regulatory activities for the three clinical stage targeted T-cell programs that Atara believes offer the most rapid path to marketing approvals. Atara and MSK also intend to expand research and development through sponsored research funded by Atara. Atara recently announced that MSK received breakthrough therapy designation from the U.S. Food and Drug Administration for its cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV - CTL) in the treatment of patients with rituxamab-refractory, EBV-associated lymphoproliferative disease.
PFE: 34.64 (+0.08), ATRA: 26.55 (+4.53)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.08 (-0.01), VIVO: 20.06 (+0.06), PETS: 15.08 (-0.05), PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), MSA: 48.84 (-0.87), PDLI: 6.96 (-0.06), BAX: 69.25 (-0.17), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), STJ: 67.14 (-0.46), TRIB: 18.60 (+0.17), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65), THRX: 19.64 (+0.08), SNY: 48.34 (+0.26)
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 22 Companies & 81 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dj7p3w/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Bioblast Pharma Ltd. - Cellular Biomedicine Group, Inc. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - OrphageniX, Inc. - Paratek Pharmaceuticals, Inc. - Pfizer Inc. - PTC Therapeutics, Inc. - Retrophin Inc. - Sarepta Therapeutics, Inc. - Trophos SA - Vybion, Inc. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/dj...l_muscular
CYTK: 7.95 (-0.02), ISIS: 70.16 (+1.50), SRPT: 14.06 (+0.70), PFE: 34.64 (+0.08), RTRX: 14.04 (+0.17), PTCT: 70.45 (+1.37), PRTK: 29.54 (-0.03), CBMG: 29.50 (-0.34), NVS: 99.04 (-0.02)
Myasthenia Gravis Therapeutics Pipeline Review H1 2015
M2 - Tue Mar 03, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/9vr3t8/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2015" report to their offering. Myasthenia Gravis - Pipeline Review, H1 2015', provides an overview of the Myasthenia Gravis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Astellas Pharma Inc. - Biokine Therapeutics Ltd. - CuraVac, Inc. - Cytokinetics, Inc. - GlaxoSmithKline plc - Grifols, S.A. - HanAll Biopharma Co., Ltd. - Neurotune AG - Pfizer Inc. - Regenesance BV - Toleranzia AB Drug Profiles - ALN-CC5 - belimumab - BKT-130 - CK-2066260 - eculizumab - GL-2045 - HL-161 - immune globulin (human) - NT-1654 - Recombinant Protein for Myasthenia Gravis - Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Regenemab - tacrolimus - tirasemtiv - Vaccine for Myasthenia Gravis For more information visit http://www.researchandmarkets.com/research/9v...nia_gravis
CYTK: 7.95 (-0.02), PFE: 34.64 (+0.08), ALXN: 182.53 (+0.02), GSK: 47.82 (+0.11)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 34.64 (+0.08), OPHT: 53.91 (+0.04), GSK: 47.82 (+0.11), PFNX: 13.60 (-0.67), LPTN: 2.93 (-0.02), AGN: 235.68 (+0.82), AAVL: 36.61 (+1.92), OHRP: 10.72 (+0.37), NVS: 99.04 (-0.02)
The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly
Dividend House - at Seeking Alpha - Mon Mar 02, 11:51PM CST
KMI: 41.04 (-0.05), ABT: 47.01 (-0.08), HAS: 62.43 (-0.29), GE: 25.66 (-0.20), MAIN: 31.12 (-0.11), HTGC: 14.46 (-0.02), TCAP: 24.60 (+0.07), DLR: 65.60 (-1.12), PFE: 34.64 (+0.08), WMT: 82.58 (-0.79), WFC: 54.82 (-0.63), UL: 43.72 (-0.33), O: 50.34 (-0.21), BMY: 65.67 (+3.75), VOD: 34.60 (-0.02), DEO: 117.00 (-0.22), TUP: 70.93 (-0.18), WTR: 26.29 (-0.16), WBA: 83.02 (-0.19), CBRL: 149.57 (-2.19), MAT: 26.38 (-0.52), OHI: 40.11 (-0.15), ABBV: 60.27 (+0.65), AFL: 62.35 (+0.07), BBL: 48.50 (-0.80), CMCSA: 60.43 (+0.47), OMI: 34.97 (-0.36)
(0)
(0)Scroll down for more posts ▼